ARS Pharmaceuticals (SPRY) Earnings Analysis
ARS Pharmaceuticals (SPRY) next reports earnings on 2026-08-12, consensus EPS -0.47655 USD. Last quarter (2026-05-15) it missed with EPS -0.61 USD vs -0.53 USD est (-15.1%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -3.01.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does SPRY next report earnings?
| Next earnings date | 2026-08-12 |
|---|---|
| Consensus EPS estimate | -0.47655 USD |
| Revenue estimate | 0.03B |
SPRY earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-15 | -0.61 USD | -0.53 USD | -15.1% | Miss |
| 2026-03-09 | -0.42 USD | -0.42 USD | 0% | Beat |
| 2025-11-10 | -0.52 USD | -0.45 USD | -15.6% | Miss |
| 2025-08-13 | -0.46 USD | -0.41 USD | -12.2% | Miss |
| 2025-03-20 | 0.52 USD | -0.04 USD | +1400% | Beat |
| 2024-11-13 | -0.2 USD | -0.18 USD | -11.1% | Miss |
Beat rate: 2/6 (33%) over reported quarters with consensus data.
SPRY valuation and analyst view
| Trailing P/E | -3.01 |
|---|---|
| Trailing EPS | -1.99379 USD |
| Price / book | 9.81 |
| Dividend yield | 0.00% |
| Market cap | 0.60B |
| Analyst consensus | Hold (4 buy / 6 hold / 0 sell) |
| Avg price target | 28.25 USD |
Related research pages
Frequently asked questions
When is ARS Pharmaceuticals (SPRY)'s next earnings date?
ARS Pharmaceuticals is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -0.47655 USD and revenue estimate of 0.03B.
Did SPRY beat earnings last quarter?
In its 2026-05-15 report, SPRY posted EPS of -0.61 USD versus a -0.53 USD estimate — a miss of 15.1%.
What is SPRY's earnings track record?
Over the last 6 reported quarters with consensus data, SPRY beat estimates 2 times (33%).
What is SPRY's current P/E ratio and EPS?
SPRY trades at a trailing P/E of -3.01 on trailing EPS of -1.9937881338064112 USD.
What do analysts rate SPRY?
Analyst consensus is "Hold" across 10 ratings (1 strong buy, 3 buy, 6 hold, 0 sell, 0 strong sell). Average 12-month price target: 28.25 USD.